Stable	O
expression	O
of	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	B-protein
protein	I-protein
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	B-protein
,	O
Pol	B-protein
,	O
and	O
Env	B-protein
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	B-protein
have	O
been	O
identified	O
that	O
inhibit	O
wild-type	O
Rev	B-protein
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O

To	O
determine	O
whether	O
such	O
transdominant	B-protein
Rev	I-protein
proteins	I-protein
could	O
provide	O
long-term	O
protection	O
against	O
HIV	O
infection	O
without	O
affecting	O
T	O
cell	O
function	O
,	O
T	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
stably	O
transduced	O
with	O
a	O
retroviral	B-DNA
vector	I-DNA
encoding	O
a	O
transdominant	O
mutant	O
of	O
the	O
Rev	B-protein
protein	I-protein
,	O
M10	B-protein
.	O

While	O
all	O
the	O
M10-expressing	B-cell_line
cell	I-cell_line
lines	I-cell_line
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV-1	O
.	O

In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	B-cell_line
CEM	I-cell_line
clones	I-cell_line
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O

Expression	O
of	O
M10	B-protein
did	O
not	O
affect	O
induction	O
of	O
HIV	O
transcription	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
regulatory	I-DNA
element	I-DNA
or	O
Tat	B-protein
.	O

Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	B-protein
M10	I-protein
did	O
not	O
alter	O
the	O
secretion	O
of	O
interleukin	B-protein
2	I-protein
in	O
response	O
to	O
mitogen	O
stimulation	O
of	O
EL-4	B-cell_line
and	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

The	O
inhibition	O
of	O
HIV	O
infection	O
in	O
cells	O
stably	O
expressing	O
a	O
transdominant	B-protein
Rev	I-protein
protein	I-protein
,	O
in	O
the	O
absence	O
of	O
any	O
deleterious	O
effect	O
on	O
T	O
cell	O
function	O
,	O
suggests	O
that	O
such	O
a	O
strategy	O
could	O
provide	O
a	O
therapeutic	O
effect	O
in	O
the	O
T	B-cell_type
lymphocytes	I-cell_type
of	O
acquired	O
immunodeficiency	O
syndrome	O
patients	O
.	O

Brief	NULL
Definitive	NULL
Report	NULL
Stable	NULL
Expression	NULL
of	NULL
Transdominant	NULL
Rev	NULL
Protein	NULL
in	NULL
Human	NULL
T	NULL
Cells	NULL
Inhibits	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Replication	NULL
By	NULL
Michael	NULL
H.	NULL
Malim	NULL
,	NULL
!	NULL

William	NULL
W.	NULL
Freimuth	NULL
,	NULL
t	NULL
JinsonF	NULL
Liu	NULL
,	NULL
*t	NULL
Terence	NULL
J.	NULL
Boyle	NULL
,	NULL
H.	NULL
Kim	NULL
Lyerly,1	NULL
Bryan	NULL
R.	NULL
Cullen	NULL
,	NULL
*	NULL
$	NULL
|	NULL
and	NULL
Gary	NULL
J.	NULL
Nabel*	NULL
}	NULL
From	NULL
the	NULL
*Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
and	NULL
the	NULL
*Departments	NULL
of	NULL
Internal	NULL
Medicine	NULL
and	NULL
Biological	NULL
Chemistry	NULL
,	NULL
University	NULL
of	NULL
Michigan	NULL
Medical	NULL
Center	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
Michigan	NULL
48109	NULL
;	NULL
and	NULL
the	NULL
Section	NULL
of	NULL
Genetics	NULL
,	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
and	NULL
the	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
1Surgery	NULL
,	NULL
Duke	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Durham	NULL
,	NULL
North	NULL
Carolina	NULL
27710	NULL
.	NULL

Summary	NULL
The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
Rev	NULL
protein	NULL
is	NULL
essential	NULL
for	NULL
viral	NULL
structural	NULL
protein	NULL
expression	NULL
(	NULL
Gag	NULL
,	NULL
Pol	NULL
,	NULL
and	NULL
Env	NULL
)	NULL
and	NULL
,	NULL
hence	NULL
,	NULL
for	NULL
viral	NULL
replication	NULL
.	NULL

In	NULL
transient	NULL
transfection	NULL
assays	NULL
,	NULL
mutant	NULL
forms	NULL
of	NULL
Rev	NULL
have	NULL
been	NULL
identified	NULL
that	NULL
inhibit	NULL
wild-type	NULL
Rev	NULL
activity	NULL
and	NULL
therefore	NULL
suppress	NULL
viral	NULL
replication	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
such	NULL
transdominant	NULL
Rev	NULL
proteins	NULL
could	NULL
provide	NULL
long-term	NULL
protection	NULL
against	NULL
HIV	NULL
infection	NULL
without	NULL
affecting	NULL
T	NULL
cell	NULL
function	NULL
,	NULL
T	NULL
leukemia	NULL
cell	NULL
lines	NULL
were	NULL
stably	NULL
transduced	NULL
with	NULL
a	NULL
retroviral	NULL
vector	NULL
encoding	NULL
a	NULL
transdominant	NULL
mutant	NULL
of	NULL
the	NULL
Rev	NULL
protein	NULL
,	NULL
M10	NULL
.	NULL

While	NULL
all	NULL
the	NULL
M10-expressing	NULL
cell	NULL
lines	NULL
remained	NULL
infectable	NULL
by	NULL
HIV-1	NULL
,	NULL
these	NULL
same	NULL
cells	NULL
failed	NULL
to	NULL
support	NULL
a	NULL
productive	NULL
replication	NULL
cycle	NULL
when	NULL
infected	NULL
with	NULL
a	NULL
cloned	NULL
isolate	NULL
of	NULL
HIV-1	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
two	NULL
out	NULL
of	NULL
three	NULL
M10-expressing	NULL
CEM	NULL
clones	NULL
were	NULL
also	NULL
resistant	NULL
to	NULL
highly	NULL
productive	NULL
infection	NULL
by	NULL
a	NULL
heterogeneous	NULL
HIV-1	NULL
pool	NULL
.	NULL

Expression	NULL
of	NULL
M10	NULL
did	NULL
not	NULL
affect	NULL
induction	NULL
of	NULL
HIV	NULL
transcription	NULL
mediated	NULL
by	NULL
the	NULL
xB	NULL
regulatory	NULL
element	NULL
or	NULL
Tat	NULL
.	NULL

Importantly	NULL
,	NULL
constitutive	NULL
expression	NULL
of	NULL
Rev	NULL
M10	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
secretion	NULL
of	NULL
interleukin	NULL
2	NULL
in	NULL
response	NULL
to	NULL
mitogen	NULL
stimulation	NULL
of	NULL
EL-4	NULL
and	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
HIV	NULL
infection	NULL
in	NULL
cells	NULL
stably	NULL
expressing	NULL
a	NULL
transdominant	NULL
Rev	NULL
protein	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
deleterious	NULL
effect	NULL
on	NULL
T	NULL
cell	NULL
function	NULL
,	NULL
suggests	NULL
that	NULL
such	NULL
a	NULL
strategy	NULL
could	NULL
provide	NULL
a	NULL
therapeutic	NULL
effect	NULL
in	NULL
the	NULL
T	NULL
lymphocytes	NULL
of	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
patients	NULL
.	NULL

Rplication	NULL
of	NULL
human	NULL
retroviruses	NULL
,	NULL
unlike	NULL
that	NULL
of	NULL
their	NULL
avian	NULL
and	NULL
murine	NULL
counterparts	NULL
,	NULL
is	NULL
dependent	NULL
upon	NULL
virally	NULL
encoded	NULL
transactivator	NULL
proteins	NULL
.	NULL

These	NULL
proteins	NULL
function	NULL
by	NULL
specifically	NULL
modulating	NULL
host	NULL
cell	NULL
processes	NULL
and	NULL
must	NULL
,	NULL
therefore	NULL
,	NULL
interact	NULL
with	NULL
host	NULL
cell	NULL
factors	NULL
.	NULL

One	NULL
approach	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
retroviral	NULL
infection	NULL
is	NULL
to	NULL
express	NULL
transdominant	NULL
forms	NULL
of	NULL
viral	NULL
transactivators	NULL
that	NULL
interfere	NULL
with	NULL
their	NULL
function	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
should	NULL
inhibition	NULL
be	NULL
achieved	NULL
by	NULL
the	NULL
interaction	NULL
of	NULL
the	NULL
mutant	NULL
protein	NULL
with	NULL
a	NULL
factor	NULL
essential	NULL
for	NULL
normal	NULL
cell	NULL
function	NULL
,	NULL
then	NULL
such	NULL
a	NULL
strategy	NULL
becomes	NULL
contrain-dicated	NULL
.	NULL

The	NULL
HIV-1	NULL
Rev	NULL
protein	NULL
is	NULL
encoded	NULL
by	NULL
a	NULL
fully	NULL
spliced	NULL
viral	NULL
mRNA	NULL
synthesized	NULL
early	NULL
in	NULL
virus	NULL
infection	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Rev	NULL
activates	NULL
the	NULL
cytoplasmic	NULL
expression	NULL
of	NULL
unspliced	NULL
viral	NULL
mRNAs	NULL
(	NULL
4-7	NULL
)	NULL
,	NULL
presumably	NULL
interacts	NULL
with	NULL
host	NULL
cell	NULL
factors	NULL
(	NULL
8-11	NULL
)	NULL
,	NULL
and	NULL
may	NULL
be	NULL
important	NULL
for	NULL
regulating	NULL
virus	NULL
latency	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Towards	NULL
the	NULL
COOH	NULL
terminus	NULL
of	NULL
Rev	NULL
,	NULL
there	NULL
is	NULL
a	NULL
well-conserved	NULL
leucine-rich	NULL
domain	NULL
that	NULL
is	NULL
absolutely	NULL
essential	NULL
for	NULL
function	NULL
(	NULL
13-16	NULL
)	NULL
.	NULL

Mutations	NULL
in	NULL
this	NULL
region	NULL
give	NULL
rise	NULL
to	NULL
defective	NULL
proteins	NULL
that	NULL
are	NULL
transdominant	NULL
inhibitors	NULL
of	NULL
Rev	NULL
function	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
(	NULL
13-16	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
analyses	NULL
have	NULL
suggested	NULL
that	NULL
inhibition	NULL
occurs	NULL
by	NULL
the	NULL
formation	NULL
of	NULL
nonfunctional	NULL
hetero-meric	NULL
Rev	NULL
multimers	NULL
unable	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
host	NULL
cell	NULL
factors	NULL
required	NULL
for	NULL
the	NULL
cytoplasmic	NULL
expression	NULL
of	NULL
unspliced	NULL
viral	NULL
mRNAs	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
transdominant	NULL
negative	NULL
mutants	NULL
of	NULL
Rev	NULL
may	NULL
represent	NULL
a	NULL
potential	NULL
strategy	NULL
for	NULL
anti-HIV	NULL
therapy	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
stable	NULL
expression	NULL
of	NULL
a	NULL
Rev	NULL
transdominant	NULL
,	NULL
M10	NULL
,	NULL
in	NULL
leukemic	NULL
T	NULL
cell	NULL
lines	NULL
are	NULL
examined	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Preparation	NULL
of	NULL
Retroviral	NULL
Vectors	NULL
and	NULL
Cell	NULL
Transduction	NULL
.	NULL

'The	NULL
PLJ	NULL
plasmid	NULL
(	NULL
18	NULL
)	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
,	NULL
filled	NULL
in	NULL
with	NULL
Klenow	NULL
,	NULL
and	NULL
digested	NULL
with	NULL
Sall	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
ligated	NULL
to	NULL
a	NULL
592-bp	NULL
insert	NULL
derived	NULL
from	NULL
GST/M10	NULL
(	NULL
17	NULL
)	NULL
,	NULL
prepared	NULL
by	NULL
digestion	NULL
with	NULL
Ncol	NULL
,	NULL
incubation	NULL
with	NULL
Klenow	NULL
enzyme	NULL
,	NULL
followed	NULL
by	NULL
digestion	NULL
with	NULL
Xhol	NULL
.	NULL

The	NULL
PLJ	NULL
cRév	NULL
M10	NULL
plasmid	NULL
was	NULL
introduced	NULL
by	NULL
calcium	NULL
phosphate	NULL
transfection	NULL
into	NULL
the	NULL
ecotropic	NULL
yCRE	NULL
virus-packaging	NULL
cell	NULL
line	NULL
(	NULL
19	NULL
)	NULL
.	NULL

1197	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
«	NULL
0022-1007/92/10/1197/05	NULL
$	NULL
2.00	NULL
Volume	NULL
176	NULL
October	NULL
1992	NULL
1197-1201	NULL
Filtered	NULL
YCRE	NULL
supernatant	NULL
collected	NULL
after	NULL
2	NULL
d	NULL
was	NULL
used	NULL
to	NULL
infect	NULL
the	NULL
amphotropic	NULL
YCRIP-packaging	NULL
line	NULL
,	NULL
which	NULL
was	NULL
then	NULL
selected	NULL
in	NULL
G418	NULL
(	NULL
1.0	NULL
mg/ml	NULL
)	NULL
.	NULL

24	NULL
clones	NULL
were	NULL
analyzed	NULL
by	NULL
titration	NULL
for	NULL
G418	NULL
resistance	NULL
,	NULL
and	NULL
three	NULL
producer	NULL
clones	NULL
were	NULL
selected	NULL
with	NULL
titers	NULL
of	NULL
Viral	NULL
supernatants	NULL
were	NULL
incubated	NULL
with	NULL
CEM	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
EL-4	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
for	NULL
4-8	NULL
h	NULL
each	NULL
day	NULL
on	NULL
four	NULL
consecutive	NULL
days	NULL
,	NULL
with	NULL
cells	NULL
maintained	NULL
otherwise	NULL
in	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Cells	NULL
were	NULL
selected	NULL
in	NULL
G418	NULL
(	NULL
1.0	NULL
mg/ml	NULL
)	NULL
and	NULL
subclones	NULL
of	NULL
G418-resistant	NULL
CEM	NULL
cells	NULL
were	NULL
isolated	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

Subclones	NULL
were	NULL
tested	NULL
for	NULL
PLJ-cREV	NULL
M1O	NULL
provirus	NULL
by	NULL
Southern	NULL
blot	NULL
analysis	NULL
by	NULL
digesting	NULL
high	NULL
molecular	NULL
weight	NULL
DNA	NULL
with	NULL
Xbal	NULL
and	NULL
probing	NULL
for	NULL
a	NULL
4.49-kb	NULL
fragment	NULL
with	NULL
the	NULL
592-bp	NULL
cREV	NULL
M10	NULL
in-sert	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
CEM	NULL
cells	NULL
were	NULL
transduced	NULL
with	NULL
a	NULL
B-galactosidase	NULL
retroviral	NULL
vector	NULL
that	NULL
confers	NULL
G418	NULL
resistance	NULL
,	NULL
BAG	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Construction	NULL
of	NULL
pIIHIB/CAT	NULL
.	NULL

-	NULL
The	NULL
replication-competent	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
-expressing	NULL
proviral	NULL
clone	NULL
,	NULL
pHIB/CAT	NULL
,	NULL
is	NULL
similar	NULL
in	NULL
design	NULL
to	NULL
vectors	NULL
described	NULL
previously	NULL
by	NULL
Terwilliger	NULL
et	NULL
al	NULL
.	NULL

(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
pIIIB/CAT	NULL
,	NULL
the	NULL
CAT	NULL
gene	NULL
has	NULL
replaced	NULL
the	NULL
5	NULL
``	NULL
portion	NULL
of	NULL
the	NULL
viral	NULL
nef	NULL
gene	NULL
and	NULL
is	NULL
therefore	NULL
,	NULL
like	NULL
Nef	NULL
,	NULL
expressed	NULL
independent	NULL
of	NULL
Rev	NULL
.	NULL

To	NULL
construct	NULL
this	NULL
vector	NULL
,	NULL
an	NULL
Ncol	NULL
site	NULL
was	NULL
introduced	NULL
at	NULL
the	NULL
initiation	NULL
codon	NULL
of	NULL
nef	NULL
in	NULL
the	NULL
pHIB	NULL
proviral	NULL
clone	NULL
(	NULL
23	NULL
)	NULL
by	NULL
targeted	NULL
mutagenesis	NULL
(	NULL
AGATGG-ACCATGG	NULL
)	NULL
.	NULL

A	NULL
681-bp	NULL
Ncol-Asp718	NULL
CAT	NULL
gene	NULL
fragment	NULL
was	NULL
generated	NULL
by	NULL
digesting	NULL
the	NULL
products	NULL
of	NULL
a	NULL
PCR	NULL
that	NULL
had	NULL
been	NULL
performed	NULL
with	NULL
primers	NULL
designed	NULL
to	NULL
introduce	NULL
these	NULL
sites	NULL
at	NULL
the	NULL
5	NULL
``	NULL
and	NULL
3	NULL
'	NULL
ends	NULL
of	NULL
CAT	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
inserted	NULL
between	NULL
the	NULL
introduced	NULL
Ncol	NULL
site	NULL
and	NULL
the	NULL
Asp718	NULL
site	NULL
(	NULL
HXB-3	NULL
isolate	NULL
,	NULL
sequence	NULL
coordinates	NULL
8374	NULL
and	NULL
8593	NULL
,	NULL
respectively	NULL
)	NULL
70	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
5	NULL
boundary	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
U3	NULL
region	NULL
.	NULL

To	NULL
partially	NULL
compensate	NULL
for	NULL
the	NULL
increased	NULL
length	NULL
of	NULL
the	NULL
virus	NULL
genome	NULL
,	NULL
the	NULL
sequences	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
U3	NULL
region	NULL
between	NULL
the	NULL
EcoRV	NULL
sites	NULL
(	NULL
sequence	NULL
coordinates	NULL
8698	NULL
and	NULL
8998	NULL
)	NULL
were	NULL
deleted	NULL
.	NULL

The	NULL
net	NULL
increase	NULL
in	NULL
genome	NULL
length	NULL
is	NULL
therefore	NULL
only	NULL
163	NULL
nucleotides	NULL
.	NULL

Cell	NULL
Culture	NULL
and	NULL
HIV	NULL
Infection	NULL
.	NULL

-	NULL
CEM	NULL
subclones	NULL
were	NULL
infected	NULL
with	NULL
0.5	NULL
mi	NULL
of	NULL
filtered	NULL
virus	NULL
supernatant	NULL
derived	NULL
from	NULL
highly	NULL
produc-	NULL
A	NULL
1000000	NULL
100000	NULL
7	NULL
10000	NULL
7	NULL
1000	NULL
4	NULL
p24	NULL
(	NULL
pg/mi	NULL
)	NULL
10	NULL
4	NULL
Days	NULL
post	NULL
infection	NULL
tive	NULL
infections	NULL
of	NULL
CEM	NULL
cells	NULL
with	NULL
the	NULL
pIIIB	NULL
or	NULL
pIIIB/CAT	NULL
molecular	NULL
clones	NULL
(	NULL
23	NULL
)	NULL
,	NULL
or	NULL
H9	NULL
cells	NULL
with	NULL
the	NULL
uncloned	NULL
,	NULL
heterogeneous	NULL
HTLV-IHB	NULL
isolate	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
at	NULL
0.5-2.5	NULL
x	NULL
10°	NULL
cells/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Virus	NULL
replication	NULL
was	NULL
monitored	NULL
over	NULL
a	NULL
4-wk	NULL
period	NULL
using	NULL
an	NULL
ELISA	NULL
system	NULL
for	NULL
soluble	NULL
p24®	NULL
expression	NULL
(	NULL
DuPont	NULL
,	NULL
NEN	NULL
,	NULL
Inc.	NULL
,	NULL
Billerica	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
after	NULL
repeated	NULL
(	NULL
four	NULL
)	NULL
cell	NULL
washes	NULL
.	NULL

As	NULL
a	NULL
negative	NULL
control	NULL
,	NULL
virus	NULL
was	NULL
heat	NULL
inactivated	NULL
by	NULL
incubation	NULL
at	NULL
56°C	NULL
for	NULL
60	NULL
min	NULL
.	NULL

IL-2	NULL
Secretion	NULL
.	NULL

-	NULL
Tl-2	NULL
gene	NULL
expression	NULL
was	NULL
stimulated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
(	NULL
40	NULL
nM	NULL
)	NULL
in	NULL
EL4	NULL
cells	NULL
or	NULL
PMA	NULL
(	NULL
40	NULL
nM	NULL
)	NULL
,	NULL
and	NULL
PHA	NULL
1	NULL
ug/ml	NULL
)	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Supernatant	NULL
was	NULL
collected	NULL
24	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

Secreted	NULL
IL-2	NULL
in	NULL
culture	NULL
supernatants	NULL
was	NULL
measured	NULL
with	NULL
the	NULL
IL-2-dependent	NULL
CTLL	NULL
cell	NULL
line	NULL
and	NULL
a	NULL
colorimetric	NULL
assay	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Cell	NULL
proliferation	NULL
expressed	NULL
as	NULL
ODs	NULL
;	NULL
»	NULL
is	NULL
on	NULL
the	NULL
ordinate	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
supernatant	NULL
in	NULL
uninduced	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
(	NULL
+	NULL
)	NULL
EL4	NULL
or	NULL
Jurkat	NULL
cells	NULL
was	NULL
10	NULL
%	NULL
.	NULL

Values	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
triplicate	NULL
determinations	NULL
,	NULL
and	NULL
SDs	NULL
were	NULL
<	NULL
10	NULL
%	NULL
.	NULL

Results	NULL
An	NULL
amphotropic	NULL
retroviral	NULL
vector	NULL
that	NULL
encodes	NULL
the	NULL
M10	NULL
mutant	NULL
of	NULL
Rev	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
control	NULL
vector	NULL
expressing	NULL
B-galac-tosidase	NULL
,	NULL
were	NULL
used	NULL
to	NULL
stably	NULL
transduce	NULL
the	NULL
leukemic	NULL
T	NULL
cell	NULL
lines	NULL
CEM	NULL
,	NULL
EL-4	NULL
,	NULL
and	NULL
Jurkat	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
effects	NULL
of	NULL
constitutive	NULL
Rev	NULL
M10	NULL
expression	NULL
in	NULL
long-term	NULL
cell	NULL
culture	NULL
,	NULL
subclones	NULL
derived	NULL
from	NULL
the	NULL
CEM-transduced	NULL
cells	NULL
were	NULL
estab-lished	NULL
.	NULL

Immunoprecipitation	NULL
analysis	NULL
with	NULL
an	NULL
anti-Rev	NULL
antiserum	NULL
confirmed	NULL
that	NULL
subclones	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
,	NULL
but	NULL
not	NULL
the	NULL
control	NULL
cells	NULL
,	NULL
expressed	NULL
the	NULL
transdominant	NULL
Rev	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Continued	NULL
expression	NULL
of	NULL
the	NULL
cell	NULL
surface	NULL
receptor	NULL
CD4	NULL
was	NULL
confirmed	NULL
by	NULL
FACS®	NULL
analysis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
cell	NULL
lines	NULL
were	NULL
next	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
support	NULL
1000000	NULL
100000	NULL
4	NULL
10000	NULL
A	NULL
=	NULL
E	NULL
best	NULL
&	NULL
a	NULL
.	NULL

1000	NULL
4	NULL
<	NULL
-S	NULL
ad	NULL
o	NULL
.	NULL

100	NULL
A	NULL
10	NULL
4	NULL
1	NULL
T	NULL
u	NULL
i	NULL
0	NULL
10	NULL
20	NULL
30	NULL
Days	NULL
post	NULL
infection	NULL
Figure	NULL
1	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
Rev	NULL
M10	NULL
protein	NULL
on	NULL
the	NULL
replication	NULL
of	NULL
cloned	NULL
(	NULL
4	NULL
)	NULL
and	NULL
uncloned	NULL
(	NULL
B	NULL
)	NULL
HIV-1	NULL
in	NULL
CEM	NULL
cells	NULL
.	NULL

The	NULL
PLJ-M10	NULL
and	NULL
PLJ-BAG	NULL
retroviral	NULL
vectors	NULL
(	NULL
20	NULL
)	NULL
were	NULL
used	NULL
to	NULL
stably	NULL
transduce	NULL
CEM	NULL
cells	NULL
(	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

After	NULL
subcloning	NULL
,	NULL
5	NULL
x	NULL
105	NULL
cells	NULL
expressing	NULL
BAG	NULL
(	NULL
MF	NULL
)	NULL
or	NULL
Rey	NULL
M10	NULL
(	NULL
C	NULL
]	NULL
)	NULL
subclone	NULL
3	NULL
;	NULL
(	NULL
A	NULL
)	NULL
subclone	NULL
4	NULL
;	NULL
(	NULL
0	NULL
)	NULL
subclone	NULL
5	NULL
were	NULL
infected	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
(	NULL
A	NULL
)	NULL
or	NULL
four	NULL
(	NULL
B	NULL
)	NULL
independent	NULL
experiments	NULL
.	NULL

1198	NULL
Stable	NULL
Expression	NULL
of	NULL
Transdominant	NULL
Rev	NULL
Protein	NULL
Inhibits	NULL
HIV	NULL
Replication	NULL
Vector	NULL
:	NULL
BAG	NULL
Rev	NULL
M10	NULL
Rev	NULL
M10	NULL
Rev	NULL
M10	NULL
Subclone	NULL
:	NULL
-	NULL
3	NULL
4	NULL
S5	NULL
-T-	NULL
T-	NULL
-T-I	NULL
TA	NULL
Es	NULL
3	NULL
E	NULL
Eq	NULL
i-	NULL
+	NULL
i-	NULL
Ee	NULL
i	NULL
i	NULL
i	NULL
i-e	NULL
pe	NULL
$	NULL
6	NULL
o	NULL
$	NULL
2	NULL
a	NULL
a	NULL
a	NULL
o	NULL
a	NULL
s	NULL
a	NULL
irus	NULL
-	NULL
¥	NULL
§	NULL
§	NULL
y	NULL
&	NULL
§oy	NULL
s	NULL
§	NULL
y	NULL
s	NULL
f	NULL
Virus	NULL
:	NULL
£	NULL
+	NULL
+	NULL
E	NULL
+	NULL
+	NULL
E	NULL
+	NULL
+	NULL
E	NULL
+	NULL
+	NULL
4	NULL
.	NULL

5008	NULL
4+	NULL
i	NULL
k.	NULL
S	NULL
§	NULL
%	NULL
-|	NULL
C	NULL
bs	NULL
L	NULL
&	NULL
4	NULL
4	NULL
3	NULL
[	NULL
=	NULL
P	NULL
O	NULL
k.	NULL
@	NULL
a	NULL
.	NULL

20	NULL
--	NULL
{	NULL
1	NULL
m	NULL
C1	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Susceptibility	NULL
of	NULL
CEM	NULL
cells	NULL
to	NULL
initial	NULL
infection	NULL
by	NULL
HIV-1	NULL
.	NULL

The	NULL
indicated	NULL
CEM	NULL
subclones	NULL
(	NULL
5	NULL
x	NULL
105	NULL
cells	NULL
)	NULL
were	NULL
either	NULL
mock	NULL
infected	NULL
with	NULL
media	NULL
alone	NULL
,	NULL
infected	NULL
with	NULL
heat-inactivated	NULL
(	NULL
HI	NULL
)	NULL
virus	NULL
,	NULL
or	NULL
infected	NULL
with	NULL
virus	NULL
derived	NULL
from	NULL
pIHB/CAT	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
washed	NULL
at	NULL
48	NULL
h	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

a	NULL
productive	NULL
infection	NULL
of	NULL
HIV-1	NULL
.	NULL

All	NULL
three	NULL
Rev	NULL
M10-expressing	NULL
subclones	NULL
were	NULL
highly	NULL
resistant	NULL
to	NULL
productive	NULL
infection	NULL
with	NULL
virus	NULL
generated	NULL
from	NULL
a	NULL
molecular	NULL
clone	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
(	NULL
23	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cells	NULL
transduced	NULL
with	NULL
the	NULL
B-galactosidase	NULL
vector	NULL
were	NULL
similar	NULL
in	NULL
susceptibility	NULL
to	NULL
nontransduced	NULL
CEM	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

When	NULL
infected	NULL
with	NULL
the	NULL
heterogeneous	NULL
HTLV-IIIB	NULL
pool	NULL
(	NULL
24	NULL
)	NULL
,	NULL
two	NULL
of	NULL
the	NULL
M10-expressing	NULL
CEM	NULL
subclones	NULL
displayed	NULL
resistance	NULL
to	NULL
highly	NULL
productive	NULL
infection	NULL
(	NULL
subclones	NULL
3	NULL
and	NULL
5	NULL
,	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

The	NULL
continuous	NULL
produc-	NULL
A	NULL
vector	NULL
:	NULL
BAG	NULL
Rev	NULL
M10	NULL
Rev	NULL
M10	NULL
Rev	NULL
M10	NULL
Subclone	NULL
:	NULL
-	NULL
3	NULL
4	NULL
5	NULL
=_	NULL
1	NULL
I	NULL
1	NULL
C	NULL
``	NULL
1	NULL
C	NULL
1	NULL
8	NULL
wiv	NULL
I	NULL
!	NULL

mks	NULL
HIV	NULL
|	NULL
'mKB	NULL
wiv	NULL
|	NULL
|mkB	NULL
wiv	NULL
|	NULL
Percentage	NULL
of	NULL
Conversion	NULL
PMA	NULL
:	NULL
604009	NULL
+	NULL
<	NULL
0	NULL
4009+	NULL
-o	NULL
£0	NULL
9+	NULL
-o	NULL
4009	NULL
+	NULL
Fold	NULL
|	NULL
Induction	NULL
:	NULL
|	NULL
5.7	NULL
121	NULL
5.9	NULL
1.0	NULL
8.9	NULL
1.1	NULL
6.5	NULL
1.4	NULL
Figure	NULL
3.	NULL
tion	NULL
of	NULL
low	NULL
,	NULL
but	NULL
detectable	NULL
levels	NULL
of	NULL
virus	NULL
by	NULL
these	NULL
cultures	NULL
suggested	NULL
that	NULL
these	NULL
subclones	NULL
were	NULL
infected	NULL
by	NULL
HIV	NULL
,	NULL
but	NULL
that	NULL
virus	NULL
failed	NULL
to	NULL
replicate	NULL
efficiently	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
subclone	NULL
4	NULL
displayed	NULL
only	NULL
a	NULL
slight	NULL
delay	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
viral	NULL
spread	NULL
relative	NULL
to	NULL
control	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
reconfirmed	NULL
the	NULL
validity	NULL
of	NULL
transdominant	NULL
Rev-mediated	NULL
protection	NULL
of	NULL
cells	NULL
against	NULL
HIV	NULL
infection	NULL
using	NULL
an	NULL
alternative	NULL
transdominent	NULL
mutant	NULL
of	NULL
Rev	NULL
,	NULL
M32	NULL
(	NULL
11	NULL
)	NULL
,	NULL
CEM-SS	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
,	NULL
and	NULL
a	NULL
double-copy	NULL
retroviral	NULL
vector	NULL
,	NULL
N2A	NULL
(	NULL
26	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

If	NULL
the	NULL
observed	NULL
resistance	NULL
of	NULL
the	NULL
CEM	NULL
cells	NULL
to	NULL
productive	NULL
HIV-1	NULL
infection	NULL
was	NULL
a	NULL
direct	NULL
consequence	NULL
of	NULL
Rev	NULL
M10	NULL
ex-pression	NULL
,	NULL
then	NULL
the	NULL
cells	NULL
should	NULL
still	NULL
be	NULL
susceptible	NULL
to	NULL
initial	NULL
infection	NULL
.	NULL

To	NULL
address	NULL
this	NULL
issue	NULL
,	NULL
a	NULL
proviral	NULL
expression	NULL
vector	NULL
pliIB/CAT	NULL
was	NULL
constructed	NULL
in	NULL
which	NULL
the	NULL
viral	NULL
nef	NULL
gene	NULL
was	NULL
replaced	NULL
with	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
.	NULL

Because	NULL
the	NULL
Nef	NULL
protein	NULL
is	NULL
expressed	NULL
early	NULL
after	NULL
HIV-1	NULL
infection	NULL
and	NULL
is	NULL
therefore	NULL
independent	NULL
of	NULL
Rev	NULL
(	NULL
3	NULL
)	NULL
,	NULL
it	NULL
is	NULL
predicted	NULL
that	NULL
,	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
pHHIB/CAT	NULL
virus	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
shortly	NULL
after	NULL
exposure	NULL
to	NULL
virus	NULL
would	NULL
be	NULL
a	NULL
measure	NULL
of	NULL
early	NULL
viral	NULL
gene	NULL
expression	NULL
and	NULL
,	NULL
hence	NULL
,	NULL
the	NULL
number	NULL
of	NULL
infectious	NULL
events	NULL
.	NULL

As	NULL
anticipated	NULL
,	NULL
all	NULL
the	NULL
CEM	NULL
lines	NULL
expressed	NULL
readily	NULL
detectable	NULL
CAT	NULL
activity	NULL
48	NULL
h	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
pHIB/CAT	NULL
virus	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

No	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
heat-inactivated	NULL
(	NULL
HI	NULL
)	NULL
virus	NULL
relative	NULL
to	NULL
mock-infected	NULL
cells	NULL
,	NULL
thus	NULL
demonstrating	NULL
that	NULL
detection	NULL
of	NULL
CAT	NULL
was	NULL
a	NULL
consequence	NULL
of	NULL
retroviral	NULL
infection	NULL
and	NULL
not	NULL
residual	NULL
inoculum	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
effect	NULL
of	NULL
Rev	NULL
M10	NULL
on	NULL
T	NULL
cell	NULL
function	NULL
,	NULL
the	NULL
CEM	NULL
subclones	NULL
were	NULL
transfected	NULL
with	NULL
HIV-CAT	NULL
reporter	NULL
plasmids	NULL
.	NULL

Mitogen	NULL
and	NULL
cytokine	NULL
induction	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
is	NULL
dependent	NULL
on	NULL
an	NULL
11-bp	NULL
sequence	NULL
recognized	NULL
by	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
(	NULL
27	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
sensitivity	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
to	NULL
NF-	NULL
«	NULL
xB	NULL
was	NULL
affected	NULL
by	NULL
the	NULL
M10	NULL
mutant	NULL
,	NULL
CAT	NULL
activity	NULL
in	NULL
each	NULL
CEM	NULL
subclone	NULL
was	NULL
determined	NULL
after	NULL
PMA	NULL
induction	NULL
.	NULL

Activation	NULL
mediated	NULL
by	NULL
the	NULL
KB	NULL
site	NULL
was	NULL
indistinguishable	NULL
between	NULL
the	NULL
three	NULL
subclones	NULL
of	NULL
CEM	NULL
M10	NULL
,	NULL
compared	NULL
with	NULL
the	NULL
B-galactosidase	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
stimulation	NULL
by	NULL
the	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
,	NULL
through	NULL
the	NULL
TAR	NULL
region	NULL
of	NULL
the	NULL
HIV-CAT	NULL
reporter	NULL
,	NULL
was	NULL
also	NULL
unaffected	NULL
in	NULL
subclones	NULL
that	NULL
stably	NULL
express	NULL
M10	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

To	NULL
B	NULL
vector	NULL
:	NULL
BAG	NULL
Rev	NULL
M10	NULL
Rev	NULL
M10	NULL
Rev	NULL
M10	NULL
Subilline	NULL
:	NULL
-	NULL
3	NULL
4	NULL
5	NULL
so	NULL
I	NULL
1	NULL
I	NULL
0d	NULL
1	NULL
mv	NULL
|	NULL
|	NULL
tar	NULL
Hiv	NULL
!	NULL

!	NULL

Tar	NULL
[	NULL
my	NULL
]	NULL
[	NULL
tar	NULL
mv	NULL
|	NULL
|	NULL
Tar	NULL
Percentage	NULL
of	NULL
Conversion	NULL
no	NULL
g	NULL
e	NULL
k	NULL
n	NULL
d	NULL
8	NULL
d	NULL
n	NULL
#	NULL
00	NULL
#	NULL
n	NULL
4	NULL
>	NULL
+	NULL
Fold	NULL
-	NULL
Induction	NULL
:	NULL
103.9	NULL
-	NULL
2.1	NULL
52.1	NULL
.	NULL

3.9	NULL
60.1	NULL
2.0	NULL
82.3	NULL
2.5	NULL
Stimulation	NULL
of	NULL
HIV-1	NULL
transcription	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
4	NULL
)	NULL
or	NULL
Tat	NULL
(	NULL
B	NULL
)	NULL
in	NULL
CEM	NULL
cells	NULL
that	NULL
stably	NULL
express	NULL
the	NULL
Rev	NULL
M10	NULL
protein	NULL
.	NULL

To	NULL
analyze	NULL
NF-	NULL
«	NULL
B	NULL
inducibility	NULL
(	NULL
A	NULL
)	NULL
,	NULL
the	NULL
indicated	NULL
CEM	NULL
subclones	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
HIV-CAT	NULL
plasmid	NULL
or	NULL
a	NULL
mutant	NULL
«	NULL
B	NULL
HIV-CAT	NULL
plasmid	NULL
before	NULL
PMA	NULL
stimulation	NULL
.	NULL

To	NULL
analyze	NULL
Tat	NULL
function	NULL
(	NULL
B	NULL
)	NULL
,	NULL
these	NULL
subclones	NULL
were	NULL
cotransfected	NULL
with	NULL
HIV-CAT	NULL
or	NULL
with	NULL
a	NULL
derivative	NULL
bearing	NULL
a	NULL
defective	NULL
TAR	NULL
element	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
incubated	NULL
(	NULL
+	NULL
)	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
,	NULL
and	NULL
CAT	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

1199	NULL
Malim	NULL
et	NULL
al	NULL
.	NULL

Brief	NULL
Definitive	NULL
Report	NULL
A	NULL
B	NULL
Cell	NULL
:	NULL
EL-4	NULL
-	NULL
EL-4	NULL
rev	NULL
M10	NULL
Cell	NULL
:	NULL
Jurkat	NULL
Jurkat	NULL
rev	NULL
M10	NULL
.50	NULL
O.D	NULL
.	NULL

570	NULL
induction	NULL
:	NULL
-o	NULL
*	NULL
-	NULL
+	NULL
-	NULL
0+	NULL
-	NULL
+	NULL
Figure	NULL
4	NULL
.	NULL

|	NULL
Induction	NULL
of	NULL
IL-2	NULL
secretion	NULL
after	NULL
stimulation	NULL
in	NULL
(	NULL
A	NULL
)	NULL
EL-4	NULL
cells	NULL
and	NULL
(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
that	NULL
express	NULL
the	NULL
Rev	NULL
M1O	NULL
protein	NULL
.	NULL

examine	NULL
more	NULL
thoroughly	NULL
the	NULL
effect	NULL
of	NULL
constitutive	NULL
M10	NULL
expression	NULL
on	NULL
the	NULL
immune	NULL
function	NULL
of	NULL
cells	NULL
,	NULL
transduced	NULL
Jurkat	NULL
and	NULL
EL-4	NULL
cell	NULL
lines	NULL
were	NULL
evaluated	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
secrete	NULL
II-2	NULL
after	NULL
mitogen	NULL
activation	NULL
.	NULL

No	NULL
difference	NULL
was	NULL
observed	NULL
with	NULL
respect	NULL
to	NULL
IL-2	NULL
secretion	NULL
in	NULL
either	NULL
cell	NULL
compared	NULL
to	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
thus	NULL
demonstrating	NULL
that	NULL
induction	NULL
of	NULL
this	NULL
lymphokine	NULL
in	NULL
cells	NULL
that	NULL
stably	NULL
expressed	NULL
the	NULL
Rev	NULL
transdominant	NULL
protein	NULL
is	NULL
unaffected	NULL
.	NULL

Discussion	NULL
The	NULL
introduction	NULL
into	NULL
susceptible	NULL
cells	NULL
of	NULL
mutant	NULL
forms	NULL
of	NULL
HIV-1	NULL
proteins	NULL
that	NULL
then	NULL
interfere	NULL
with	NULL
viral	NULL
replication	NULL
represents	NULL
an	NULL
attractive	NULL
approach	NULL
to	NULL
the	NULL
treatment	NULL
of	NULL
HIV-1	NULL
infection	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Although	NULL
analogues	NULL
of	NULL
HIV-1	NULL
nucleic	NULL
acid	NULL
structures	NULL
,	NULL
such	NULL
as	NULL
TAR	NULL
or	NULL
RRE	NULL
,	NULL
have	NULL
been	NULL
used	NULL
to	NULL
inhibit	NULL
HIV	NULL
replication	NULL
in	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
,	NULL
the	NULL
potential	NULL
of	NULL
mutant	NULL
viral	NULL
proteins	NULL
to	NULL
achieve	NULL
this	NULL
effect	NULL
,	NULL
and	NULL
their	NULL
ability	NULL
to	NULL
interfere	NULL
with	NULL
normal	NULL
cellular	NULL
function	NULL
,	NULL
remain	NULL
unknown	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
a	NULL
substantial	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
T	NULL
cells	NULL
that	NULL
constitutively	NULL
express	NULL
the	NULL
Rev	NULL
M10	NULL
transdominant	NULL
mutant	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
transdominant	NULL
Rev-expressing	NULL
lines	NULL
vary	NULL
in	NULL
their	NULL
initial	NULL
sus-	NULL
ceptibility	NULL
to	NULL
HIV-1	NULL
infection	NULL
by	NULL
no	NULL
more	NULL
than	NULL
twofold	NULL
relative	NULL
to	NULL
the	NULL
control	NULL
,	NULL
BAG-expressing	NULL
,	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

These	NULL
data	NULL
support	NULL
the	NULL
conclusion	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
resistance	NULL
of	NULL
the	NULL
CEM	NULL
cells	NULL
to	NULL
HIV-1	NULL
infection	NULL
is	NULL
directly	NULL
due	NULL
to	NULL
the	NULL
M10	NULL
protein	NULL
,	NULL
which	NULL
inhibits	NULL
productive	NULL
infection	NULL
by	NULL
preventing	NULL
expression	NULL
of	NULL
viral	NULL
structural	NULL
proteins	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
Rev	NULL
M10	NULL
protection	NULL
has	NULL
been	NULL
analyzed	NULL
previously	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
RNA	NULL
binding	NULL
and	NULL
multimerization	NULL
domains	NULL
of	NULL
M10	NULL
are	NULL
intact	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
Rev	NULL
M10	NULL
multimerizes	NULL
and	NULL
precludes	NULL
the	NULL
binding	NULL
of	NULL
wild-type	NULL
Rev	NULL
to	NULL
the	NULL
RRE	NULL
and	NULL
subsequent	NULL
interactions	NULL
with	NULL
the	NULL
cellular	NULL
factors	NULL
that	NULL
facilitate	NULL
the	NULL
cytoplasmic	NULL
expression	NULL
of	NULL
unspliced	NULL
viral	NULL
RNA	NULL
(	NULL
17	NULL
)	NULL
.	NULL

We	NULL
speculate	NULL
that	NULL
subclone	NULL
4	NULL
displayed	NULL
only	NULL
a	NULL
delay	NULL
in	NULL
the	NULL
onset	NULL
of	NULL
acute	NULL
infection	NULL
with	NULL
HTLV-IIIB	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
,	NULL
because	NULL
it	NULL
appears	NULL
to	NULL
show	NULL
increased	NULL
susceptibility	NULL
to	NULL
initial	NULL
infection	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
CAT	NULL
infection	NULL
experiment	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
relative	NULL
to	NULL
the	NULL
other	NULL
lines	NULL
.	NULL

Importantly	NULL
,	NULL
expression	NULL
of	NULL
Rev	NULL
M10	NULL
protein	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
several	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
,	NULL
including	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
,	NULL
those	NULL
required	NULL
for	NULL
Tat	NULL
function	NULL
,	NULL
and	NULL
the	NULL
multiple	NULL
regulatory	NULL
proteins	NULL
that	NULL
control	NULL
IL-2	NULL
synthesis	NULL
.	NULL

Although	NULL
the	NULL
possibility	NULL
remains	NULL
that	NULL
Rev	NULL
M10	NULL
may	NULL
affect	NULL
other	NULL
activation	NULL
pathways	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
stable	NULL
expression	NULL
of	NULL
Rev	NULL
M10	NULL
does	NULL
not	NULL
adversely	NULL
affect	NULL
T	NULL
cell	NULL
function	NULL
globally	NULL
.	NULL

The	NULL
Rev	NULL
M10	NULL
protein	NULL
therefore	NULL
represents	NULL
a	NULL
gene	NULL
product	NULL
that	NULL
might	NULL
preclude	NULL
efficient	NULL
HIV-1	NULL
replication	NULL
without	NULL
adversely	NULL
affecting	NULL
T	NULL
cell	NULL
function	NULL
.	NULL

Although	NULL
differential	NULL
protection	NULL
by	NULL
Rev	NULL
M10	NULL
was	NULL
observed	NULL
in	NULL
separate	NULL
subclones	NULL
with	NULL
the	NULL
uncloned	NULL
virus	NULL
pool	NULL
,	NULL
resistance	NULL
need	NULL
not	NULL
be	NULL
conferred	NULL
equally	NULL
on	NULL
all	NULL
T	NULL
cells	NULL
to	NULL
provide	NULL
a	NULL
therapeutic	NULL
effect	NULL
.	NULL

For	NULL
example	NULL
,	NULL
T	NULL
cell	NULL
clones	NULL
rendered	NULL
resistant	NULL
to	NULL
HIV-1	NULL
could	NULL
proliferate	NULL
to	NULL
reconstitute	NULL
the	NULL
immune	NULL
system	NULL
of	NULL
an	NULL
infected	NULL
host	NULL
.	NULL

Because	NULL
multiple	NULL
cells	NULL
can	NULL
be	NULL
transduced	NULL
,	NULL
protection	NULL
against	NULL
HIV-1-induced	NULL
disease	NULL
might	NULL
be	NULL
achieved	NULL
by	NULL
transducing	NULL
sufficiently	NULL
large	NULL
numbers	NULL
of	NULL
cells	NULL
with	NULL
Rev	NULL
M10	NULL
.	NULL

This	NULL
gene	NULL
could	NULL
be	NULL
readily	NULL
introduced	NULL
into	NULL
peripheral	NULL
CD4*	NULL
T	NULL
cells	NULL
or	NULL
eventually	NULL
into	NULL
progenitor	NULL
cells	NULL
that	NULL
give	NULL
rise	NULL
to	NULL
mature	NULL
CD4*	NULL
populations	NULL
.	NULL

This	NULL
strategy	NULL
might	NULL
,	NULL
therefore	NULL
,	NULL
be	NULL
used	NULL
to	NULL
slow	NULL
the	NULL
progression	NULL
of	NULL
AIDS	NULL
in	NULL
asymptomatic	NULL
HIV-1-infected	NULL
patients	NULL
or	NULL
,	NULL
possibly	NULL
,	NULL
might	NULL
be	NULL
used	NULL
to	NULL
restore	NULL
immune	NULL
function	NULL
in	NULL
individuals	NULL
that	NULL
have	NULL
progressed	NULL
to	NULL
later	NULL
disease	NULL
stages	NULL
.	NULL

We	NULL
thank	NULL
Donna	NULL
Gschwend	NULL
for	NULL
typing	NULL
assistance	NULL
and	NULL
Xu	NULL
Ling	NULL
for	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
U.S.	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
AI-29821	NULL
(	NULL
B.	NULL
R.	NULL
Cullen	NULL
and	NULL
M.	NULL
H.	NULL
Malim	NULL
)	NULL
,	NULL
and	NULL
AI-26865	NULL
and	NULL
AI-29179	NULL
(	NULL
G.	NULL
J.	NULL
Nabel	NULL
)	NULL
.	NULL

W.	NULL
W.	NULL
Freimuth	NULL
was	NULL
supported	NULL
by	NULL
an	NULL
Arthritis	NULL
Foun-	NULL
dation	NULL
Postdoctoral	NULL
Fellowship	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Gary	NULL
J.	NULL
Nabel	NULL
,	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
Research	NULL
Laboratories	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Michigan	NULL
Medical	NULL
Center	NULL
,	NULL
MSRB	NULL
I	NULL
,	NULL
Room	NULL
4510	NULL
,	NULL
1150	NULL
West	NULL
Medical	NULL
Center	NULL
Drive	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
48109	NULL
.	NULL

M.	NULL
H.	NULL
Malim	NULL
's	NULL
present	NULL
address	NULL
is	NULL
the	NULL
Department	NULL
of	NULL
Microbiology	NULL
in	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Pennsylvania	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
19104	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
12	NULL
June	NULL
1992	NULL
.	NULL

1200	NULL
Stable	NULL
Expression	NULL
of	NULL
Transdominant	NULL
Rev	NULL
Protein	NULL
Inhibits	NULL
HIV	NULL
Replication	NULL
References	NULL
1	NULL
.	NULL

2	NULL
.	NULL

3	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

Herskowitz	NULL
,	NULL
I	NULL
.	NULL

1987	NULL
.	NULL

Functional	NULL
inactivation	NULL
of	NULL
genes	NULL
by	NULL
dominant	NULL
negative	NULL
mutations	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

329:219	NULL
.	NULL

Baltimore	NULL
,	NULL
D.	NULL
1988	NULL
.	NULL

Intracellular	NULL
immunization	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

335:395	NULL
.	NULL

Kim	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Bytn	NULL
,	NULL
J.	NULL
Groopman	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

Temporal	NULL
aspects	NULL
of	NULL
DNA	NULL
and	NULL
RNA	NULL
synthesis	NULL
during	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
:	NULL
evidence	NULL
for	NULL
differential	NULL
gene	NULL
expression	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3708.	NULL
.	NULL

Malim	NULL
,	NULL
M.H	NULL
.	NULL

,	NULL
J.	NULL
Hauber	NULL
,	NULL
SY	NULL
.	NULL

Le	NULL
,	NULL
JV	NULL
.	NULL

Maizel	NULL
,	NULL
and	NULL
BR	NULL
.	NULL

Cullen	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
HIV-1	NULL
rev	NULL
trans-activator	NULL
acts	NULL
through	NULL
a	NULL
structured	NULL
target	NULL
sequence	NULL
to	NULL
activate	NULL
nuclear	NULL
export	NULL
of	NULL
unspliced	NULL
viral	NULL
mRNA	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

338:254.	NULL
.	NULL

Felber	NULL
,	NULL
BK	NULL
.	NULL

,	NULL
M.	NULL
Hadzopoulou-Cladaras	NULL
,	NULL
C.	NULL
Clederas	NULL
,	NULL
and	NULL
T.	NULL
Copeland	NULL
.	NULL

1989	NULL
.	NULL

Rev	NULL
protein	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
affects	NULL
the	NULL
stability	NULL
and	NULL
transport	NULL
of	NULL
the	NULL
viral	NULL
mRNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:1495.	NULL
.	NULL

Hammarskjold	NULL
,	NULL
M.L	NULL
.	NULL

,	NULL
J.	NULL
Heimer	NULL
,	NULL
B.	NULL
Hammarskjold	NULL
,	NULL
I.	NULL
Sangwan	NULL
,	NULL
L.	NULL
Albert	NULL
,	NULL
and	NULL
D.	NULL
Rekosh	NULL
.	NULL

1989	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
env	NULL
expression	NULL
by	NULL
the	NULL
rev	NULL
gene	NULL
product	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1959.	NULL
.	NULL

Emerman	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
Vazeux	NULL
,	NULL
and	NULL
K.	NULL
Peden	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
rev	NULL
gene	NULL
product	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
affects	NULL
envelope-specific	NULL
RNA	NULL
localization	NULL
.	NULL

Cell	NULL
.	NULL

57:1156.	NULL
.	NULL

Chang	NULL
,	NULL
D.D	NULL
.	NULL

,	NULL
and	NULL
P.A	NULL
.	NULL

Sharp	NULL
.	NULL

1989	NULL
.	NULL

Regulation	NULL
by	NULL
HIV	NULL
Rev	NULL
depends	NULL
upon	NULL
recognition	NULL
of	NULL
splice	NULL
sites	NULL
.	NULL

Cell	NULL
.	NULL

59:789.	NULL
.	NULL

Lu	NULL
,	NULL
X.	NULL
,	NULL
J.	NULL
Heimer	NULL
,	NULL
D.	NULL
Rekosh	NULL
,	NULL
and	NULL
M.L	NULL
.	NULL

Hammarskjold	NULL
.	NULL

1990	NULL
.	NULL

U1	NULL
small	NULL
nuclear	NULL
RNA	NULL
plays	NULL
a	NULL
direct	NULL
role	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
rev-regulated	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
envy	NULL
mRNA	NULL
that	NULL
remains	NULL
unspliced	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

87:7598	NULL
.	NULL

Fankhauser	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Izaurralde	NULL
,	NULL
Y.	NULL
Adachi	NULL
,	NULL
P.	NULL
Wingfield	NULL
,	NULL
and	NULL
U.K.	NULL
Laemmli	NULL
.	NULL

1991	NULL
.	NULL

Specific	NULL
complex	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
rev	NULL
and	NULL
nucleolar	NULL
B23	NULL
proteins	NULL
:	NULL
dissociation	NULL
by	NULL
the	NULL
Rev	NULL
response	NULL
element	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:2567	NULL
.	NULL

Malim	NULL
,	NULL
M.H	NULL
.	NULL

,	NULL
D.F	NULL
.	NULL

McCarn	NULL
,	NULL
L.S	NULL
.	NULL

Tiley	NULL
,	NULL
and	NULL
B.R	NULL
.	NULL

Cullen	NULL
.	NULL

1991	NULL
.	NULL

Mutational	NULL
definition	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Rev	NULL
activation	NULL
domain	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4248	NULL
.	NULL

Pomerantz	NULL
,	NULL
R.J.	NULL
,	NULL
D.	NULL
Trono	NULL
,	NULL
M.B	NULL
.	NULL

Feinberg	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Cells	NULL
nonproductively	NULL
infected	NULL
with	NULL
HIV-1	NULL
exhibit	NULL
an	NULL
aberrant	NULL
pattern	NULL
of	NULL
viral	NULL
RNA	NULL
expression	NULL
:	NULL
a	NULL
molecular	NULL
model	NULL
for	NULL
latency	NULL
.	NULL

Cell	NULL
.	NULL

61:1271	NULL
.	NULL

Malim	NULL
,	NULL
M.H	NULL
.	NULL

,	NULL
S.	NULL
Bohnlein	NULL
,	NULL
J.	NULL
Hauber	NULL
,	NULL
and	NULL
B.R	NULL
.	NULL

Cullen	NULL
.	NULL

1989	NULL
.	NULL

Functional	NULL
dissection	NULL
of	NULL
the	NULL
HIV-1	NULL
Rev	NULL
trans-activator-derivation	NULL
of	NULL
a	NULL
trans-dominant	NULL
repressor	NULL
of	NULL
Rev	NULL
function	NULL
.	NULL

Cell	NULL
.	NULL

58:205	NULL
.	NULL

Mermer	NULL
,	NULL
B.	NULL
,	NULL
BK	NULL
.	NULL

Felber	NULL
,	NULL
M.	NULL
Campbell	NULL
,	NULL
and	NULL
G.N	NULL
.	NULL

Paviakis	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
trans-dominant	NULL
HIV-1	NULL
Rev	NULL
protein	NULL
mutanix	NULL
by	NULL
direct	NULL
transfer	NULL
of	NULL
bacterially	NULL
produced	NULL
proteins	NULL
into	NULL
human	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18:2037	NULL
.	NULL

Olsen	NULL
,	NULL
H.S	NULL
.	NULL

,	NULL
AW	NULL
.	NULL

Cochrane	NULL
,	NULL
PJ	NULL
.	NULL

Dillon	NULL
,	NULL
C.M	NULL
.	NULL

Nalin	NULL
,	NULL
and	NULL
C.A	NULL
.	NULL

Rosen	NULL
.	NULL

1990	NULL
.	NULL

Interaction	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Rev	NULL
protein	NULL
with	NULL
a	NULL
structured	NULL
region	NULL
in	NULL
env	NULL
mRNA	NULL
1201	NULL
Malim	NULL
et	NULL
al	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29.	NULL
is	NULL
dependent	NULL
on	NULL
multimer	NULL
formation	NULL
mediated	NULL
through	NULL
a	NULL
basic	NULL
stretch	NULL
of	NULL
amino	NULL
acids	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

4:1357	NULL
.	NULL

Venkatesh	NULL
,	NULL
LK	NULL
.	NULL

,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1990	NULL
.	NULL

Mutants	NULL
in	NULL
a	NULL
conserved	NULL
region	NULL
near	NULL
the	NULL
carboxy-terminus	NULL
of	NULL
HIV-1	NULL
Rev	NULL
identify	NULL
functionally	NULL
important	NULL
residues	NULL
and	NULL
exhibit	NULL
a	NULL
dominant	NULL
negative	NULL
phenotype	NULL
.	NULL

Virology	NULL
.	NULL

178:327	NULL
.	NULL

Malim	NULL
,	NULL
M.H	NULL
.	NULL

,	NULL
and	NULL
BR	NULL
.	NULL

Cullen	NULL
.	NULL

1991	NULL
.	NULL

HIV-1	NULL
structural	NULL
gene	NULL
expression	NULL
requires	NULL
the	NULL
binding	NULL
of	NULL
multiple	NULL
Rev	NULL
monomers	NULL
to	NULL
the	NULL
viral	NULL
RRE-implications	NULL
for	NULL
HIV-1	NULL
latency	NULL
.	NULL

Cell	NULL
.	NULL

65:241	NULL
.	NULL

Korman	NULL
,	NULL
A.J	NULL
.	NULL

,	NULL
J.D	NULL
.	NULL

Frantz	NULL
,	NULL
J.L	NULL
.	NULL

Strominger	NULL
,	NULL
and	NULL
R.C	NULL
.	NULL

Mulligan	NULL
.	NULL

1987	NULL
.	NULL

Expression	NULL
of	NULL
human	NULL
class	NULL
II	NULL
major	NULL
histocompati-bility	NULL
complex	NULL
antigens	NULL
using	NULL
retrovirus	NULL
vectors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:2150	NULL
.	NULL

Danos	NULL
,	NULL
O.	NULL
,	NULL
and	NULL
R.C	NULL
.	NULL

Mulligan	NULL
.	NULL

1988	NULL
.	NULL

Safe	NULL
and	NULL
efficient	NULL
generation	NULL
of	NULL
recombinant	NULL
retroviruses	NULL
with	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
host	NULL
ranges	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

85:6460	NULL
.	NULL

Price	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Turner	NULL
,	NULL
and	NULL
C.	NULL
Cepko	NULL
.	NULL

1987	NULL
.	NULL

Lineage	NULL
analysis	NULL
in	NULL
the	NULL
vertebrate	NULL
nervous	NULL
system	NULL
by	NULL
retrovirus-mediated	NULL
gene	NULL
transfer	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:156	NULL
.	NULL

Nabel	NULL
,	NULL
EG	NULL
.	NULL

,	NULL
G.	NULL
Plautz	NULL
,	NULL
FM	NULL
.	NULL

Boyce	NULL
,	NULL
J.C.	NULL
Stanley	NULL
,	NULL
and	NULL
G.J	NULL
.	NULL

Nabel	NULL
.	NULL

1989	NULL
.	NULL

Recombinant	NULL
gene	NULL
expression	NULL
in	NULL
vivo	NULL
within	NULL
en-dothelial	NULL
cells	NULL
of	NULL
the	NULL
arterial	NULL
wall	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

244:1342	NULL
.	NULL

Terwilliger	NULL
,	NULL
E.F.	NULL
,	NULL
B.	NULL
Godin	NULL
,	NULL
J.G	NULL
.	NULL

Sodroski	NULL
,	NULL
and	NULL
W.A	NULL
.	NULL

Hasel-tine	NULL
.	NULL

1989	NULL
.	NULL

Construction	NULL
and	NULL
use	NULL
of	NULL
a	NULL
replication-competent	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV-1	NULL
)	NULL
that	NULL
expresses	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
enzyme	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:3857	NULL
.	NULL

Hwang	NULL
,	NULL
S.S.	NULL
,	NULL
T.J.	NULL
Boyle	NULL
,	NULL
HK	NULL
.	NULL

Lyerly	NULL
,	NULL
and	NULL
B.R	NULL
.	NULL

Cullen	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
envelope	NULL
V3	NULL
loop	NULL
as	NULL
the	NULL
primary	NULL
determinant	NULL
of	NULL
cell	NULL
tropism	NULL
in	NULL
HIV-1	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

253:71	NULL
.	NULL

Popovic	NULL
,	NULL
M.	NULL
,	NULL
M.G	NULL
.	NULL

Sarngadharan	NULL
,	NULL
E.	NULL
Read	NULL
,	NULL
and	NULL
R.C	NULL
.	NULL

Gallo	NULL
.	NULL

1984	NULL
.	NULL

Detection	NULL
,	NULL
isolation	NULL
,	NULL
and	NULL
continuous	NULL
production	NULL
of	NULL
cytopathic	NULL
retroviruses	NULL
(	NULL
HTLV-III	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
and	NULL
pre-AIDS	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

224:497	NULL
.	NULL

Nara	NULL
,	NULL
PL	NULL
.	NULL

,	NULL
and	NULL
P.J	NULL
.	NULL

Fischinger	NULL
.	NULL

1988	NULL
.	NULL

Quantitative	NULL
infectivity	NULL
assay	NULL
for	NULL
HIV-1	NULL
and	NULL
-2	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

332:469	NULL
.	NULL

Hantzopoulos	NULL
,	NULL
PA.	NULL
,	NULL
B.A	NULL
.	NULL

Sullenger	NULL
,	NULL
G.	NULL
Ungers	NULL
,	NULL
and	NULL
E.	NULL
Gilboa	NULL
.	NULL

1989	NULL
.	NULL

Improved	NULL
gene	NULL
expression	NULL
upon	NULL
transfer	NULL
of	NULL
the	NULL
adeno-sine	NULL
deaminase	NULL
minigene	NULL
outside	NULL
of	NULL
the	NULL
transcriptional	NULL
unit	NULL
of	NULL
a	NULL
retroviral	NULL
vector	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:3519	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

326:711	NULL
(	NULL
erratum	NULL
.	NULL

344:178	NULL
)	NULL
.	NULL

Sullenger	NULL
,	NULL
B.A	NULL
.	NULL

,	NULL
H.F.	NULL
Gallardo	NULL
,	NULL
G.E	NULL
.	NULL

Ungers	NULL
,	NULL
and	NULL
E.	NULL
Gilboa	NULL
.	NULL

1990	NULL
.	NULL

Overexpression	NULL
of	NULL
TAR	NULL
sequences	NULL
renders	NULL
cells	NULL
resistant	NULL
to	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
replication	NULL
.	NULL

Cell	NULL
.	NULL

63:601	NULL
.	NULL

Nabel	NULL
,	NULL
G.J	NULL
.	NULL

,	NULL
S.A.	NULL
Rice	NULL
,	NULL
D.M	NULL
.	NULL

Knipe	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Alternative	NULL
mechanisms	NULL
for	NULL
activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

239:1299	NULL
.	NULL

Brief	NULL
Definitive	NULL
Report	NULL

